BSE Live
Mar 30, 16:01Prev. Close
1557.20
Open Price
1556.85
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 30, 15:58Prev. Close
1558.40
Open Price
1548.00
Bid Price (Qty.)
1504.80 (83)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Caplin Point Laboratories (in Rs. Cr.) | Jun 10 | Jun 09 | Jun 08 | Mar 07 | Jun 06 | |
| 12 mths | 12 mths | 15 mths | 9 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 3.65 | 3.21 | 1.31 | 2.31 | 2.58 | |
| Net CashFlow From Operating Activities | 0.27 | 12.17 | 1.11 | 2.39 | 1.57 | |
| Net Cash Used In Investing Activities | -4.72 | -3.55 | -0.58 | -1.26 | -10.64 | |
| Net Cash Used From Financing Activities | 2.18 | -2.04 | 3.81 | -3.30 | 14.77 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -2.27 | 6.58 | 4.34 | -2.16 | 5.70 | |
| Cash And Cash Equivalents Begin of Year | 16.91 | 10.33 | 5.99 | 5.78 | 0.08 | |
| Cash And Cash Equivalents End Of Year | 14.64 | 16.91 | 10.33 | 3.62 | 5.78 |
10.02.2026
Caplin Labs Consolidated December 2025 Net Sales at Rs 542.77 crore, up 10.1% Y-o-Y
09.02.2026
Caplin Labs Standalone December 2025 Net Sales at Rs 189.22 crore, up 2.15% Y-o-Y
12.11.2025
Caplin Labs Standalone September 2025 Net Sales at Rs 175.18 crore, down 15.75% Y-o-Y
05.11.2025
Caplin Labs Consolidated September 2025 Net Sales at Rs 534.04 crore, up 10.54% Y-o-Y
30.03.2026
29.03.2026
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth